Showing all 11 results
-
Sale!
Adbry
$6,599.25Adbry tralokinumab-ldrm represents a promising new treatment option for patients with moderate to severe asthma. By targeting IL-13,
One of the key advantages of tralokinumab-ldrm is its targeted mechanism of action.
-
Sale!
Cibinqo
$1,320.00 – $1,555.99Cibinqo is a breakthrough medication for the treatment of moderate-to-severe atopic dermatitis that offers several advanced effects,
including a rapid onset of action, improvement in the quality of life, and a convenient and practical delivery system.
-
Sale!
Ilumya Tildrakizumab
$15,999.00Ilumya tildrakizumab is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy (treatment using ultraviolet or UV light).
Tildrakizumab, sold under the brand names Ilumya and Ilumetri, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders.[2] It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union.
-
Sale!
Olumiant
$1,050.00 – $3,545.00Olumiant is a promising treatment option for individuals with rheumatoid arthritis and psoriatic arthritis.
It has a quick onset of action and may be used as a monotherapy without the need for additional medications.
-
Sale!
Opzelura Ruxolitinib
$1,549.99Opzelura (ruxolitinib) is a prescription cream used on the skin (topical) to treat mild to moderate eczema (atopic dermatitis) in patients 12 years or older who aren’t suitable for or have failed other topical prescription drugs.
ruxolitinib represents an advanced therapy for the treatment of atopic dermatitis.
-
Sale!
Skilarence
$100.00Skilarence is a highly advanced medication that offers effective, long-term control of psoriasis symptoms.
This is a major advantage for individuals with psoriasis, as this condition is caused by an overactive immune response that attacks healthy skin cells.
-
Sale!
Skyrizi Risankizumab
$15,345.00Skyrizi (risankizumab) is a medication used to treat adults with Plaque Psoriasis and Psoriatic Arthritis.
Risankizumab has been approved in the European Union,[6] the United States,[5][8] and Canada[9] for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. In Japan, it is approved for treating plaque psoriasis,
-
Sale!
Stelara
$16,299.00 – $32,400.00Stelara (ustekinumab) is a biologic medication used to treat moderate to severe plaque psoriasis and active psoriatic arthritis.
It targets the immune system’s proteins that cause inflammation and is administered via injection by a healthcare provider.
-
Sale!
Takhzyro
$16,599.00Takhzyro is a highly effective treatment for HAE that provides significant relief to patients. Its long-lasting effect,
Several studies have demonstrated the efficacy of Takhzyro in the treatment of these conditions.
-
Sale!
Taltz
$2,500.00 – $3,600.00Taltz is a highly effective treatment for moderate to severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.
Taltz’s advanced effects in treating these conditions are well documented in clinical trials and have been shown to significantly improve patient outcomes.
-
Sale!
Tremfya
$2,550.00Tremfya is also very convenient for patients to use. The drug is administered as a subcutaneous injection, which means that it is injected under the skin.
This is a promising development for patients who suffer from both conditions, as currently available treatments for psoriatic arthritis are limited.
